JP2020529834A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020529834A5 JP2020529834A5 JP2019571593A JP2019571593A JP2020529834A5 JP 2020529834 A5 JP2020529834 A5 JP 2020529834A5 JP 2019571593 A JP2019571593 A JP 2019571593A JP 2019571593 A JP2019571593 A JP 2019571593A JP 2020529834 A5 JP2020529834 A5 JP 2020529834A5
- Authority
- JP
- Japan
- Prior art keywords
- modified human
- genetically modified
- cell
- interest
- exogenous
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001744 T-lymphocyte Anatomy 0.000 claims 12
- 108091008874 T cell receptors Proteins 0.000 claims 6
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 claims 6
- 108020005067 RNA Splice Sites Proteins 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 4
- 101150087698 alpha gene Proteins 0.000 claims 3
- 210000004027 cell Anatomy 0.000 claims 3
- 108091026890 Coding region Proteins 0.000 claims 2
- 102100029452 T cell receptor alpha chain constant Human genes 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 108091033409 CRISPR Proteins 0.000 claims 1
- 238000010354 CRISPR gene editing Methods 0.000 claims 1
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 claims 1
- 101000634853 Homo sapiens T cell receptor alpha chain constant Proteins 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 108010017070 Zinc Finger Nucleases Proteins 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 238000011144 upstream manufacturing Methods 0.000 claims 1
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022022074A JP2022078103A (ja) | 2017-06-30 | 2022-02-16 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2023133418A JP2023175699A (ja) | 2017-06-30 | 2023-08-18 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2025026102A JP2025102755A (ja) | 2017-06-30 | 2025-02-20 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2025172936A JP2026027250A (ja) | 2017-06-30 | 2025-10-14 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762527845P | 2017-06-30 | 2017-06-30 | |
| US62/527,845 | 2017-06-30 | ||
| US201762579473P | 2017-10-31 | 2017-10-31 | |
| US62/579,473 | 2017-10-31 | ||
| PCT/US2018/039740 WO2019005957A1 (en) | 2017-06-30 | 2018-06-27 | GENETICALLY MODIFIED T CELLS COMPRISING A MODIFIED INTRON IN THE ALPHA T CELL RECEPTOR GENE |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022074A Division JP2022078103A (ja) | 2017-06-30 | 2022-02-16 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020529834A JP2020529834A (ja) | 2020-10-15 |
| JP2020529834A5 true JP2020529834A5 (cg-RX-API-DMAC7.html) | 2021-08-05 |
Family
ID=63103995
Family Applications (5)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019571593A Pending JP2020529834A (ja) | 2017-06-30 | 2018-06-27 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2022022074A Pending JP2022078103A (ja) | 2017-06-30 | 2022-02-16 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2023133418A Withdrawn JP2023175699A (ja) | 2017-06-30 | 2023-08-18 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2025026102A Pending JP2025102755A (ja) | 2017-06-30 | 2025-02-20 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2025172936A Pending JP2026027250A (ja) | 2017-06-30 | 2025-10-14 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
Family Applications After (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022022074A Pending JP2022078103A (ja) | 2017-06-30 | 2022-02-16 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2023133418A Withdrawn JP2023175699A (ja) | 2017-06-30 | 2023-08-18 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2025026102A Pending JP2025102755A (ja) | 2017-06-30 | 2025-02-20 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
| JP2025172936A Pending JP2026027250A (ja) | 2017-06-30 | 2025-10-14 | T細胞受容体アルファ遺伝子の改変されたイントロンを含む遺伝子改変t細胞 |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US11053484B2 (cg-RX-API-DMAC7.html) |
| EP (2) | EP4775669A2 (cg-RX-API-DMAC7.html) |
| JP (5) | JP2020529834A (cg-RX-API-DMAC7.html) |
| AU (3) | AU2018292526A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3068465A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES3067983T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2019005957A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| EP4775669A2 (en) * | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| US11952408B2 (en) | 2017-10-03 | 2024-04-09 | Juno Therapeutics, Inc. | HPV-specific binding molecules |
| CN112585276A (zh) * | 2018-04-05 | 2021-03-30 | 朱诺治疗学股份有限公司 | 产生表达重组受体的细胞的方法和相关组合物 |
| KR102617818B1 (ko) | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
| MX2021011782A (es) * | 2019-03-27 | 2021-12-10 | Res Inst Nationwide Childrens Hospital | Generación de células nk primarias del receptor de antígeno quimérico (car) para la inmunoterapia al cáncer usando una combinación de virus cas9/rnp y aav. |
| CN114026228A (zh) | 2019-05-07 | 2022-02-08 | 精密生物科学公司 | 用于识别序列的工程化大范围核酸酶的优化 |
| US20220411479A1 (en) * | 2019-10-30 | 2022-12-29 | Precision Biosciences, Inc. | Cd20 chimeric antigen receptors and methods of use for immunotherapy |
| EP4110356A4 (en) * | 2020-02-28 | 2024-03-27 | Wisconsin Alumni Research Foundation | NON-VIRAL GENERATION OF CHIMERIC ANTIGEN RECEPTOR T CELLS OBTAINED BY GENE EDITING |
| GB202005184D0 (en) * | 2020-04-08 | 2020-05-20 | Autolus Ltd | Method |
| WO2021231259A1 (en) | 2020-05-11 | 2021-11-18 | Precision Biosciences, Inc. | Self-limiting viral vectors encoding nucleases |
| WO2022132756A1 (en) * | 2020-12-14 | 2022-06-23 | Emendobio Inc. | Biallelic knockout of trac |
| AU2022368911A1 (en) | 2021-10-19 | 2024-05-30 | Precision Biosciences, Inc. | Gene editing methods for treating alpha-1 antitrypsin (aat) deficiency |
| EP4493697A4 (en) * | 2022-03-16 | 2026-06-10 | Univ Minnesota | GENETICALLY MODIFIED T LYMPHOCYTES FOR CELL THERAPY |
| WO2025165787A1 (en) * | 2024-02-01 | 2025-08-07 | The Board Of Trustees Of The Leland Stanford Junior University | Touchless selection of gene modified cell therapies through trac intron knockins |
Family Cites Families (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4873192A (en) | 1987-02-17 | 1989-10-10 | The United States Of America As Represented By The Department Of Health And Human Services | Process for site specific mutagenesis without phenotypic selection |
| JP4012243B2 (ja) | 1994-01-18 | 2007-11-21 | ザ スクリップス リサーチ インスティチュート | 亜鉛フィンガータンパク質誘導体およびそのための方法 |
| US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
| GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
| CA2196419C (en) | 1994-08-20 | 2007-08-21 | Yen Choo | Improvements in or relating to binding proteins for recognition of dna |
| US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
| GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| US6015832A (en) | 1997-12-31 | 2000-01-18 | The Regents Of The University Of Michigan | Methods of inactivating bacteria including bacterial spores |
| US6635676B2 (en) | 1999-04-28 | 2003-10-21 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US7767216B2 (en) | 1999-04-28 | 2010-08-03 | The Regents Of The University Of Michigan | Antimicrobial compositions and methods of use |
| US6559189B2 (en) | 1999-04-28 | 2003-05-06 | Regents Of The University Of Michigan | Non-toxic antimicrobial compositions and methods of use |
| US6506803B1 (en) | 1999-04-28 | 2003-01-14 | Regents Of The University Of Michigan | Methods of preventing and treating microbial infections |
| US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
| AU2001263155A1 (en) | 2000-05-16 | 2001-11-26 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
| US6555674B2 (en) | 2000-08-09 | 2003-04-29 | Nsgene A/S | JeT promoter |
| GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
| ATE347593T1 (de) | 2002-01-23 | 2006-12-15 | Univ Utah Res Found | Zielgerichtete chromosomale mutagenese mit zinkfingernukleasen |
| US20100151556A1 (en) * | 2002-03-15 | 2010-06-17 | Cellectis | Hybrid and single chain meganucleases and use thereof |
| EP1504092B2 (en) | 2002-03-21 | 2014-06-25 | Sangamo BioSciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
| US9447434B2 (en) | 2002-09-05 | 2016-09-20 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
| US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
| US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
| EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
| DK3246403T3 (da) | 2005-10-18 | 2020-10-26 | Prec Biosciences | Rationelt designede meganucleaser med ændret sekvens-specificitet og dna-bindende affinitet |
| WO2008102199A1 (en) | 2007-02-20 | 2008-08-28 | Cellectis | Meganuclease variants cleaving a dna target sequence from the beta-2-microglobulin gene and uses thereof |
| ES2422291T3 (es) | 2007-10-31 | 2013-09-10 | Prec Biosciences Inc | Meganucleasas monocatenarias diseñadas racionalmente con secuencias de reconocimiento no palindrómicas |
| EP2329017A2 (en) | 2008-08-04 | 2011-06-08 | Cellectis | Novel method to generate meganucleases with altered characteristics |
| CA2735456C (en) | 2008-08-26 | 2021-11-16 | City Of Hope | Method and compositions for enhanced anti-tumor effector functioning of t cells |
| EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
| WO2011059836A2 (en) | 2009-10-29 | 2011-05-19 | Trustees Of Dartmouth College | T cell receptor-deficient t cell compositions |
| US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| PT2816112T (pt) | 2009-12-10 | 2018-11-20 | Univ Iowa State Res Found Inc | Modificação do adn modificada pelo efector tal |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
| EP3683319A1 (en) | 2011-06-01 | 2020-07-22 | Precision Biosciences, Inc. | Methods and products for producing engineered mammalian cell lines with amplified transgenes |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| KR20140019635A (ko) | 2012-08-06 | 2014-02-17 | 엘지이노텍 주식회사 | 발광 소자 및 발광 소자 패키지 |
| US8697359B1 (en) | 2012-12-12 | 2014-04-15 | The Broad Institute, Inc. | CRISPR-Cas systems and methods for altering expression of gene products |
| AU2014235968B2 (en) | 2013-03-21 | 2018-05-24 | Ospedale San Raffaele Srl | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
| US11311575B2 (en) | 2013-05-13 | 2022-04-26 | Cellectis | Methods for engineering highly active T cell for immunotherapy |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法 |
| CA2913872C (en) | 2013-05-31 | 2022-01-18 | Cellectis | A laglidadg homing endonuclease cleaving the t-cell receptor alpha gene and uses thereof |
| CA2913871C (en) | 2013-05-31 | 2021-07-13 | Cellectis | A laglidadg homing endonuclease cleaving the c-c chemokine receptor type-5 (ccr5) gene and uses thereof |
| EP3058072B1 (en) | 2013-10-17 | 2021-05-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| DK3105317T3 (en) | 2014-02-14 | 2019-01-14 | Cellectis | Immunotherapy cells that are genetically engineered to target antigen on both immune cells and pathological cells |
| RU2752933C2 (ru) | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| AU2015229299A1 (en) | 2014-03-12 | 2016-09-22 | Precision Biosciences, Inc. | Dystrophin gene exon deletion using engineered nucleases |
| WO2015167766A1 (en) | 2014-04-29 | 2015-11-05 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Ccr5 disruption of cells expressing anti-hiv chimeric antigen receptor (car) derived from broadly neutralizing antibodies |
| DK3152312T3 (da) | 2014-06-06 | 2020-04-06 | Regeneron Pharma | Fremgangsmåder og sammensætninger til modifikation af et mållocus |
| US20160081314A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric Antigen Receptors |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| BR112017020750A2 (en) * | 2015-03-27 | 2018-06-26 | President And Fellows Of Harvard College | modified t-cells and methods of producing and using them |
| US9790490B2 (en) | 2015-06-18 | 2017-10-17 | The Broad Institute Inc. | CRISPR enzymes and systems |
| CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
| EP4339287A3 (en) | 2015-07-31 | 2024-05-22 | Regents Of The University Of Minnesota | Modified cells and methods of therapy |
| ES2768984T3 (es) | 2015-10-05 | 2020-06-24 | Prec Biosciences Inc | Meganucleasas diseñadas con secuencias de reconocimiento encontradas en el gen de la región constante alfa del receptor de células T humanas |
| ES2803728T3 (es) | 2015-10-05 | 2021-01-29 | Prec Biosciences Inc | Células genéticamente modificadas que comprenden un gen de región constante alfa del receptor de linfocitos T humano modificado |
| WO2017070429A1 (en) | 2015-10-22 | 2017-04-27 | Regents Of The University Of Minnesota | Methods involving editing polynucleotides that encode t cell receptor |
| US20190017075A1 (en) | 2015-12-23 | 2019-01-17 | Precision Biosciences, Inc. | Engineered meganucleases with recognition sequences found in the human beta-2 microglobulin gene |
| US20190241910A1 (en) | 2016-03-11 | 2019-08-08 | Bluebird Bio, Inc. | Genome edited immune effector cells |
| KR102614675B1 (ko) | 2016-04-15 | 2023-12-19 | 메모리얼 슬로안 케터링 캔서 센터 | 유전자이식 t 세포 및 키메라 항원 수용체 t 세포 조성물 및 관련 방법 |
| EP4775669A2 (en) * | 2017-06-30 | 2026-07-15 | Precision Biosciences, Inc. | Genetically-modified t cells comprising a modified intron in the t cell receptor alpha gene |
| KR102617818B1 (ko) | 2018-04-12 | 2023-12-27 | 프리시젼 바이오사이언시스 인코포레이티드 | 인간 t 세포 수용체 알파 불변 영역 유전자에 대한 특이성을 갖는 최적화된 조작된 뉴클레아제 |
-
2018
- 2018-06-27 EP EP26158413.0A patent/EP4775669A2/en active Pending
- 2018-06-27 EP EP18749901.7A patent/EP3645038B1/en active Active
- 2018-06-27 US US16/627,052 patent/US11053484B2/en active Active
- 2018-06-27 CA CA3068465A patent/CA3068465A1/en active Pending
- 2018-06-27 ES ES18749901T patent/ES3067983T3/es active Active
- 2018-06-27 WO PCT/US2018/039740 patent/WO2019005957A1/en not_active Ceased
- 2018-06-27 JP JP2019571593A patent/JP2020529834A/ja active Pending
- 2018-06-27 AU AU2018292526A patent/AU2018292526A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/330,365 patent/US12448613B2/en active Active
-
2022
- 2022-02-16 JP JP2022022074A patent/JP2022078103A/ja active Pending
-
2023
- 2023-08-18 JP JP2023133418A patent/JP2023175699A/ja not_active Withdrawn
-
2025
- 2025-02-20 JP JP2025026102A patent/JP2025102755A/ja active Pending
- 2025-05-21 AU AU2025203753A patent/AU2025203753A1/en not_active Abandoned
- 2025-10-14 JP JP2025172936A patent/JP2026027250A/ja active Pending
-
2026
- 2026-05-28 AU AU2026204135A patent/AU2026204135A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7461445B2 (ja) | Hla-cw8拘束性の変異krasを認識するt細胞受容体 | |
| Atsavapranee et al. | Delivery technologies for T cell gene editing: applications in cancer immunotherapy | |
| Miliotou et al. | CAR T-cell therapy: a new era in cancer immunotherapy | |
| Tichet et al. | Bispecific PD1-IL2v and anti-PD-L1 break tumor immunity resistance by enhancing stem-like tumor-reactive CD8+ T cells and reprogramming macrophages | |
| Buechler et al. | Fibroblast-macrophage reciprocal interactions in health, fibrosis, and cancer | |
| Brightman et al. | Harnessing neoantigen specific CD4 T cells for cancer immunotherapy | |
| Xi et al. | Genetically engineered pigs for xenotransplantation: Hopes and challenges | |
| Zeng et al. | Exhausted T cells and epigenetic status | |
| AU2016427822B2 (en) | Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogennous FOXP3 gene | |
| CN110612446B (zh) | 分离新抗原-特异性t细胞受体序列的方法 | |
| JP2019511236A5 (cg-RX-API-DMAC7.html) | ||
| IL299249B2 (en) | Genetically-modified immune cells comprising a microrna-adapted shrna (shrnamir) | |
| Chudnovskiy et al. | Proximity-dependent labeling identifies dendritic cells that drive the tumor-specific CD4+ T cell response | |
| FI3599251T3 (fi) | Cd20-antigeeniin kohdentuvan kimeerisen antigeenireseptorin rakentaminen ja sillä muunnettujen t-solujen aktiivisuuden tunnistaminen | |
| JP2021521849A5 (cg-RX-API-DMAC7.html) | ||
| JP2021518160A5 (cg-RX-API-DMAC7.html) | ||
| JP2018510657A5 (cg-RX-API-DMAC7.html) | ||
| Keith et al. | Leading edge: emerging drug, cell, and gene therapies for junctional epidermolysis bullosa | |
| CA3186620A1 (en) | Methods and compositions for editing the b2m locus in b cells | |
| JP2022524509A (ja) | Cd40lの組成と調整可能な制御のための方法 | |
| Fesnak et al. | Clinical development and manufacture of chimeric antigen receptor T cells and the role of leukapheresis | |
| Zhou et al. | Regulatory T cell dysfunction and immunotherapeutic breakthroughs in type 1 diabetes | |
| Gerbitz et al. | Stromal interferon-γ signaling and cross-presentation are required to eliminate antigen-loss variants of B cell lymphomas in mice | |
| Özdemir | Role of immune cells in the tumor microenvironment | |
| Helm et al. | Targeting c-MYC with T-cells |